Pharmacological Treatment of Perianal Gland Tumors in Male Dogs
Abstract
:Simple Summary
Abstract
1. Introduction
2. Material and Methods
Statistical Analysis
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Allison, K.H.; Hammond, M.E.H.; Dowsett, M.; McKernin, S.E.; Carey, L.A.; Fitzgibbons, P.L.; Hayes, D.F.; Lakhani, S.R.; Chavez-MacGregor, M.; Perlmutter, J.; et al. Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. Arch. Pathol. Lab. Med. 2020, 144, 545–563. [Google Scholar] [CrossRef] [Green Version]
- Barradell, L.B.; Faulds, D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994, 5, 59–80. [Google Scholar] [CrossRef]
- Bray, J. Tumours of the Perianal Region; Dobson, J.M., Lascelles, B.D.X., Eds.; BSAVA Manual of Canine and Feline Oncology: Birmingham, UK, 2011; pp. 223–228. [Google Scholar]
- Brodzki, A.; Łopuszyński, W.; Millan, Y.; Tatara, M.R.; Brodzki, P.; Kulpa, K.; Minakow, N. Androgen and estrogen receptor expression in different types of perianal gland tumors in male dogs. Animals 2021, 11, 875. [Google Scholar] [CrossRef]
- Brodzki, P.; Wrona, Z.; Krakowski, L.; Brodzki, A. The influence of tamoxifen on the sexual impulse and semen biological value in male dogs. Bull. Vet. Ins. Pulawy 2007, 51, 383–391. [Google Scholar]
- Brodzki, A.; Tatara, M.R.; Brodzki, P.; Balicki, I. DNA Adduct assessment during antihormonal treatment of perianal gland tumors with tamoxifen in male dogs. Vivo 2019, 33, 731–735. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Brodzki, P.; Wrona, Z.; Piech, T.; Brodzki, A. Effects of cytostatics on the selected parameters of cell-mediated immunity in dogs. Bull. Vet. Inst. Pulawy 2011, 55, 87–93. [Google Scholar]
- Burdzińska, A.; Idziak, M. Perianal gland tumors in dogs. Mag. Wet. 2008, 16, 1130–1134. [Google Scholar]
- Brunetti, B.; Bacci, B.; Angeli, C.; Benazzi, C.; Muscatello, L.V. p53, ER, and Ki67 expression in canine mammary carcinomas and correlation with pathological variables and prognosis. Vet. Pathol. 2021, 58, 325–331. [Google Scholar] [CrossRef]
- Chang, C.C.; Tsai, M.H.; Liao, J.W.; Chan, J.P.; Wong, M.L.; Chang, S.C. Evaluation of hormone receptor expression for use in predicting survival of female dogs with malignant mammary gland tumors. J. Am. Vet. Med. Assoc. 2009, 15, 391–396. [Google Scholar] [CrossRef]
- Corrada, Y.; Arias, D.; Rodriguez, R.; Spaini, E.; Fava, F.; Gobello, C. Effect of tamoxifen citrate on reproductive parameters of male dogs. Theriogenology 2004, 61, 1327–1341. [Google Scholar] [CrossRef]
- De Marchi, T.; Foekens, J.A.; Umar, A.; Martens, J.W. Endocrine therapy resistance in estrogen receptor (ER) positive breast cancer. Drug Discov. Today 2016, 21, 1181–1188. [Google Scholar] [CrossRef] [PubMed]
- De Las Mulas, J.M.; Millán, Y.; Dios, R.A. Pprospective analysis of immunohistochemically determined estrogen receptor alpha and progesterone receptor expression and host and tumor factors as predictors of disease-free period in mammary tumors of the dog. Vet. Pathol. 2005, 42, 200–212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- De Voogt, H.J.; Smith, P.H.; Pavone-Macaluso, M.; de Pauw, M.; Suciu, S. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762. J. Urol. 1986, 135, 303–307. [Google Scholar] [PubMed]
- Dunnwald, L.K.; Rossing, M.A.; Li, C.I. Hormone receptor status, tumor characteristics, and prognosis: A prospective cohort of breast cancer patients. Breast Cancer Res. 2007, 9, R6. [Google Scholar] [CrossRef] [PubMed]
- Goldenberg, S.L.; Bruchovsky, N. Use of cyproterone acetate in prostate cancer. Urol. Clin. N. Am. 1991, 18, 111–122. [Google Scholar] [CrossRef]
- Goldschmidt, M.; Hendrick, M. Tumours of the Skin and Soft Tissue. In Tumors in Domestic Animals; Meuten, D., Ed.; Iowa State University Press: Ames, IA, USA, 2002; pp. 68–70. [Google Scholar]
- Goldschmidt, M.H.; Dunstan, R.W.; Stannard, A.A.; Tscharner, C.; Walder, E.J.; Yager, J.A. Histological Classification of Epithelial and Melanocytic Tumors of the Skin of Domestic Animals. In World Heatlh Organization International Histological Classification of Tumors of Domestic Animals, 2nd ed.; Armed Forces Institute of Pathology: Washington, DC, USA, 1998; Volume III. [Google Scholar]
- Hua, H.; Zhang, H.; Kong, Q.; Jiang, Y. Mechanisms for estrogen receptor expression in human cancer. Exp. Hematol. Oncol. 2018, 7, 24. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jakab, C.; Rusvai, M.; Glif, P.; Kulka, J. Expression of Claudin-7 molecule in canine perianal gland tumours. Acta Vet. Brno. 2010, 79, 127–133. [Google Scholar] [CrossRef] [Green Version]
- Javanbakht, J.; Tavassoli, A.; Sasani, F.; Sabbagh, A.; Hassan, M.A.; Samakkhah, A.S.; Shafiee, R.; Jani, M.; Alimohammadi, S.; Samani, R.; et al. An overall assessment of circumanal gland adenoma in a terrier mix breed dog. Asian Pac. J. Trop. Biomed. 2013, 3, 580–583. [Google Scholar] [CrossRef] [Green Version]
- Jeromin, L.; Sosnowski, M.; Lipinski, M. Cyproterone acetate (CPA) in the treatment of advanced prostatic cancer. Urol. Polska. 1997, 50, 1. [Google Scholar]
- Kay, C.; Martínez-Pérez, C.; Meehan, J.; Gray, M.; Webber, V.; Dixon, J.M.; Turnbull, A.K. Current trends in the treatment of HR+/HER2+ breast cancer. Future Oncol. 2021, 17, 1665–1681. [Google Scholar] [CrossRef]
- Louie, M.C.; Sevigny, M.B. Steroid hormone receptors as prognostic mark-ers in breast cancer. Am. J. Cancer Res. 2017, 7, 1617–1636. [Google Scholar]
- Manna, S.; Holz, M.K. Tamoxifen Action in ER-Negative Breast Cancer. Signal Transduct. Insights 2016, 10, 1–7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Martin, P.M.; Cotard, M.; Mialot, J.P.; André, F.; Raynaud, J.P. Animal models for hormone-dependent human breast cancer. Relationship between steroid receptor profiles in canine and feline mammary tumors and survival rate. Cancer Chemother. Pharmacol. 1984, 12, 13–17. [Google Scholar] [CrossRef] [PubMed]
- Maughan, K.L.; Lutterbie, M.A.; Ham, P.S. Treatment of breast cancer. Am. Fam. Phys. 2010, 81, 1339–1346. [Google Scholar]
- Metcalf, S.; Petri, B.J.; Kruer, T.; Green, B.; Dougherty, S.; Wittliff, J.L.; Klinge, C.M.; Clem, B.F. Serine synthesis influences tamoxifen response in ER+ human breast carcinoma. Endocr. Relat. Cancer 2021, 28, 27–37. [Google Scholar] [CrossRef]
- Millán, Y.; Guil-Luna, S.; Reymundo, C.; Sánchez-Céspedes, R.; Martín de las Mulas, J. Sex steroid hormones and tumors in domestic animals. In Insights from Vetterinary Medicine; Payan-Carreira, R., Ed.; InTech: London, UK, 2013. [Google Scholar] [CrossRef]
- Morris, J.S.; Dobson, J.M.; Bostock, D.E. Use of tamoxifen in the control of canine mammary neoplasia. Vet. Rec. 1993, 133, 539–542. [Google Scholar] [CrossRef]
- Morris, J.; Dobson, J. Small Animal Oncology; Blackwell Science Ltd.: London, UK, 2001. [Google Scholar]
- Nolte, I.; Nolte, M. Practical Oncology in Dog and Cat; Enke im Hippokrates Verlag: Stuttgart, Germany, 2000. [Google Scholar]
- Pisani, G.; Millanta, F.; Lorenzi, D.; Vannozzi, I.; Poli, A. Androgen receptor expression in normal, hyperplastic and neoplastic hepatoid glands in the dog. Res. Vet. Sci. 2006, 81, 231–236. [Google Scholar] [CrossRef] [PubMed]
- Scott, W.W.; Wade, J.C. Medical treatment of benign nodular prostatic hyperplasia with cyproterone acetate. J. Urol. 1969, 101, 81–85. [Google Scholar] [CrossRef]
- Sobczyńska-Rak, A.; Brodzki, A. VEGF and 17-β-estradiol levels after tamoxifen administration in canine hepatoid gland adenomas and hepatoid gland epitheliomas. Vivo 2014, 28, 871–877. [Google Scholar]
- Spoerri, M.; Guscetti, F.; Hartnack, S.; Boos, A.; Oei Balogh, O.; Nowaczyk, R.M.; Michel, E.; Reichler, I.M.; Kowalewski, M.P. Endocrine control of canine mammary neoplasms: Serum reproductive hormone levels and tissue expression of steroid hormone, prolactin and growth hormone receptors. BMC Vet. Res. 2015, 11, 235. [Google Scholar] [CrossRef] [Green Version]
- Tavares, W.L.; Lavalle, G.E.; Figueiredo, M.S.; Souza, A.G.; Bertagnolli, A.C.; AB Viana, F.; Paes, P.R.; A Carneiro, R.; Cavalcanti, G.A.; Melo, M.M.; et al. Evaluation of adverse effects in tamoxifen exposed healthy female dogs. Acta Vet. Scand. 2010, 52, 67. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Teo, M.Y.; Rathkopf, D.E.; Kantoff, P. Treatment of advanced prostate cancer. Annu. Rev. Med. 2019, 70, 479–499. [Google Scholar] [CrossRef] [PubMed]
- Tozon, N.; Kodre, V.; Sersa, G.; Cemazar, M. Effective treatment of perianal tumors in dogs with electrochemotherapy. Anticancer Res. 2005, 25, 839–846. [Google Scholar] [PubMed]
- Tozon, N.; Kodre, V.; Juntes, P.; Sersa, G.; Cemazar, M. Electrochemotherapy is highly effective for the treatment of canine perianal hepatoid adenoma and epithelioma. Acta Vet. 2010, 60, 285–302. [Google Scholar] [CrossRef]
- Tunc, A.S.; Alcigir, M.E.; Atalay-Vural, S. Concurrent metastatic hepatoid gland carcinoma and oesophagogastric leiomyosarcoma in a dog. Ank. Üniv. Vet. Fak. Derg. 2014, 61, 29–34. [Google Scholar]
Adenoma | Epithelioma | Carcinoma | |
---|---|---|---|
Before treatment (baseline) | 9.00 (4.00) | 10.00 (4.75) | 11.00 (4.50) |
After 1 month of treatment | 6.00 (4.50) | 6.50 (3.75) | 8.00 (3.00) |
After 2 months of treatment | 5.00 (3.50) | 5.00 (2.50) | 8.00 (3.00) |
After 3 months of treatment | 2.00 (3.00) *** | 3.50 (2.00) ** | 9.00 (3.50) |
After 6 months of treatment | 0.00 (0.00) *** | 0.00 (2.25) *** | 9.00 (3.00) |
After 12 months of treatment | 0.00 (0.00) *** | 3.50 (4.00) *** | 8.00 (3.00) |
After 18 months of treatment | 0.00 (0.00) *** | 1.50 (3.75) *** | 7.00 (3.00) * |
After 24 months of treatment | 0.00 (0.00) *** | 0.00 (3.75) *** | 7.00 (2.00) * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Brodzki, A.; Łopuszyński, W.; Brodzki, P.; Głodkowska, K.; Knap, B.; Gawin, P. Pharmacological Treatment of Perianal Gland Tumors in Male Dogs. Animals 2023, 13, 463. https://doi.org/10.3390/ani13030463
Brodzki A, Łopuszyński W, Brodzki P, Głodkowska K, Knap B, Gawin P. Pharmacological Treatment of Perianal Gland Tumors in Male Dogs. Animals. 2023; 13(3):463. https://doi.org/10.3390/ani13030463
Chicago/Turabian StyleBrodzki, Adam, Wojciech Łopuszyński, Piotr Brodzki, Katarzyna Głodkowska, Bartosz Knap, and Paulina Gawin. 2023. "Pharmacological Treatment of Perianal Gland Tumors in Male Dogs" Animals 13, no. 3: 463. https://doi.org/10.3390/ani13030463